The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Neznamov G.G.

Nauchno-issledovatel'skiĭ institut farmakologii imeni V.V. Zakusova RAMN, Moskva

Dorofeeva O.A.

Zakusov Institute of Pharmacology, Moscow, Russia

Metlina M.V.

Zakusov Institute of Pharmacology, Moscow, Russia

Syunyakov T.S.

Zakusov Research Institute of Pharmacology, Moscow, Russia

Minaev S.V.

Kafedra detskoĭ khirurgii s kursom anesteziologii i reanimatologii GOU VPO Stavropol'skaia gosudarstvennaia meditsinskaia akademiia Federal'nogo agentstva po zdravookhraneniiu i sotsial'nomu razvitiiu

Ivashkina N.Yu.

Zakusov Research Institute of Pharmacology, Moscow, Russia

Martyanov V.A.

Zakusov Research Institute of Pharmacology, Moscow, Russia

Seredenin S.B.

Zakusov Research Institute of Pharmacology, Russian Academy of Sciences, Moscow

Results of a clinical study of a new anxiolytic, a blocker of central cholecystokinin receptors

Authors:

Neznamov G.G., Dorofeeva O.A., Metlina M.V., Syunyakov T.S., Minaev S.V., Ivashkina N.Yu., Martyanov V.A., Seredenin S.B.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(8): 53‑60

DOI: 10.17116/jnevro201911908153

Read: 2110 times

Download PDF (RU)
Contact the author
Table of contents

RESULTS OF A CLINICAL STUDY OF A NEW ANXIOLYTIC, A BLOCKER OF CENTRAL CHOLECYSTOKININ RECEPTORS
RESULTS OF A CLINICAL STUDY OF A NEW ANXIOLYTIC, A BLOCKER OF CENTRAL CHOLECYSTOKININ RECEPTORS

To cite this article:

Neznamov GG, Dorofeeva OA, Metlina MV, et al. . Results of a clinical study of a new anxiolytic, a blocker of central cholecystokinin receptors. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(8):53‑60. (In Russ.)
https://doi.org/10.17116/jnevro201911908153

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Como­rbid anxiety diso­rders in patients with neurological pathology: current state of the problem and the role of etifoxine in treatment stra­tegy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):126-136
Abstract:

Objective. To evaluate anxiolytic action of GB-115, a low-affinity blocker of central cholecystokinin receptors, used in tablets in a dose of 1 mg for the treatment of patients with anxiety disorders in order to determine effective dose, safety, tolerability and efficacy in clinical settings. Material and methods. The study included 31 patients (22 women, 9 men) diagnosed with generalized anxiety disorder (GAD, F41.1 according to ICD-10), aged from 22 to 53 years. The duration of treatment was 21 days. The Hamilton Anxiety Rating scale, Psychopathologic symptoms severity evaluation scale (PSSES), Spilberger State-Anxiety Inventory, Multidimensional Fatigue Inventory (MFI), Clinical Global Impression scale (CGI), computerized battery for evaluation of cognitive functions (“NS-Psychotest”) were used. Results and conclusion. The effective dose of GB-115 was determined at 6 mg per day. Drug action is characterized by fast onset of anxiolytic effect with stimulating properties and beneficial effect on sleep disturbances and autonomic symptoms. GB-115 treatment was associated with favorable changes in attention parameters, reaction time and overall performance. In contrast to first-line drugs for GAD treatment (SSRIs and SNRIs), GB-115 does not induce initial overactivation, anxiety and sleep disturbances. GB-115 is safe and has a good tolerability.

Keywords:

new anxiolytic
blocker of cholecystokinin receptors
generalized anxiety disorder

Authors:

Neznamov G.G.

Nauchno-issledovatel'skiĭ institut farmakologii imeni V.V. Zakusova RAMN, Moskva

Dorofeeva O.A.

Zakusov Institute of Pharmacology, Moscow, Russia

Metlina M.V.

Zakusov Institute of Pharmacology, Moscow, Russia

Syunyakov T.S.

Zakusov Research Institute of Pharmacology, Moscow, Russia

Minaev S.V.

Kafedra detskoĭ khirurgii s kursom anesteziologii i reanimatologii GOU VPO Stavropol'skaia gosudarstvennaia meditsinskaia akademiia Federal'nogo agentstva po zdravookhraneniiu i sotsial'nomu razvitiiu

Ivashkina N.Yu.

Zakusov Research Institute of Pharmacology, Moscow, Russia

Martyanov V.A.

Zakusov Research Institute of Pharmacology, Moscow, Russia

Seredenin S.B.

Zakusov Research Institute of Pharmacology, Russian Academy of Sciences, Moscow

Close metadata

References:

  1. Baxter AJ, Scott KM, Vos T, Whiteford HA. Global prevalence of anxiety disorders: A systematic review and meta-regression. Psychological Medicine. 2013;43(5):897-910. https://doi.org/10.1017/S003329171200147X
  2. Chisholm D, Sweeny K, Sheehan P, Rasmussen B, Smit F, Cuijpers P, Saxena S. Scaling-up treatment of depression and anxiety: a global return on investment analysis. Lancet Psychiatry. 2016;3(5):415-424. https://doi.org/10.1016/S2215-0366(16)30024-4
  3. Voronina TA, Seredenin SB. Perspektivy poiska novyx anksiolitikov. Eksperim i Klin Farmakologiya. 2002;5:4-17. (In Russ.) https://doi.org/10.30906/0869-2092-2002-65-5-4-17
  4. Seredenin SB. Lekcii po farmakogenetike. M.: MIA; 2004. (In Russ.)
  5. Seredenin SB. Sozdanie novykh anksiolitikov s pozitsij mul’tifaktorial’nogo kontrolya trevozhnykh reaktsij. Psikhofarmakologiya i Biol Narkologiya (Spets. vyp.). 2007;7(2):2-1944. (In Russ.)
  6. Bourin M, Baker GB, Bradwejn J. Neurobiology of panic disorder. J of Psychosom Res. 1998;44(1):163-180. https://doi.org/10.1016/s0022-3999(97)00203-1
  7. Noble F, Roques BP. Cholecystokinin peptides in brain function. Handbook of Neurochemistry and Molecular Neurobiology. Springer. New York: NY, USA; 2006. https://doi.org/10.1007/0-387-30395-2_24
  8. Schalling M, Friberg K, Seroogy K, Riederer P, Bird E, Schiffmann SN, Mailleux P, Vanderhaeghen JJ, Kuga S, Goldstein M, Kitahama K, Luppi PH, Jouvet M, Hokfelt T. Analysis of expression of cholecystokinin in dopamine cells in the ventral mesencephalon of several species and in humans with schizophrenia. Proc Natl Acad Sci USA. 1990;87:8427-8431. https://doi.org/10.1073/pnas.87.21.8427
  9. Boyce S, Rupniak NMJ, Steventon M, Iversen SD. CCK-8S inhibits L-dopa-induced dyskinesia in parkinsonian squirel monkeys. Neurology. 1990;40:717-718. https://doi.org/10.1212/wnl.40.4.717
  10. Bradwejn J, Koszycki D, du Tertre AC, van Megen H, den Boer J, Westenberg H, Annable L. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry. 1994;51(6):486-493. https://doi.org/10.1001/archpsyc.1994.03950060050005
  11. Chopin Ph, Briley M. The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze. Psychopharmacology. 1993;110:409-414. https://doi.org/10.1007/bf02244646
  12. Seredenin SB, Gudasheva TA, Kolik LG. Zameshchennyye triptofansoderzhashchiye dipeptidy s kholetsistokininonegativnoy ili kholetsistokininopozitivnoy aktivnostyu. Patent RF na izobreteniye №2227144/20.04.04. Ssylka aktivna na 30.07.17. (In Russ.). http://www.freepatent.ru/patents/2227144
  13. Kolik LG, Zhukov VN, Seredenin SB. Xarakter proyavleniya antinociceptivny’x i anksioliticheskix svojstv soedineniya GB-115 v aspekte vzaimodejstviya xolecistokininovoj i opioidergicheskoj sistem. Eksperimentalnaya i Klinicheskaya Farmakologiya. 2007;70(2):8-11. (In Russ.)
  14. Kolik LG, Gudasheva TA, Seredenin SB. Role of the Cholecystokinin System in Anxiolytic Activity of Dipeptide GB-115. Bulletin of Experimental Biology and Medicine. 2012;153(6):852-855. (In Russ.) https://doi.org/10.1007/s10517-012-1842-1
  15. Kolik LG, Konstantinopolsky MA, Ryibina IV, Povarnina PYu, Gudasheva TA, Seredenin SB. Anxiolytic Activity of Dipeptide GB-115 after Oral Administration. Bulletin of Experimental Biology and Medicine. 2013;155(2):200-203. (In Russ.) https://doi.org/10.1007/s10517-013-2112-6
  16. Kolik LG, Garibova TL, Litvinova SA, Kuzneczova AL, Kapicza IG, Kadnikov IA, Gudasheva TA, Voronina TA, Seredenin SB. Otsutstvie tolerantnosti i sindroma otmeny’ u novogo L-triptofansoderzhashhego dipeptidnogo anksiolitika GB-115. Vestnik RAMN. 2011;7:37-42. (In Russ.)
  17. Gudasheva TA, Lezina VP, Kir’yanova EP, Deeva OA, Kolik LG, Seredenin SB. Issledovanie biologicheski aktivnoj konformacii GB-115, dipeptidnogo analoga xolecistokinina-4. Bioorganicheskaya Khimiya. 2013;39(3):293-302. (In Russ.) https://doi.org/10.7868/S0132342313030068
  18. Gudasheva TA, Zherdev VP, Kolik LG, Koly’vanov GB, Litvin AA, Seredenin SB, Smirnov VV. Klinicheskaya farmakokinetika original’nogo dipeptidnogo anksiolitika GB-115. Klinicheskaya Farmakokinetika i Farmakodinamika. 2017;1:52-56. (In Russ.)
  19. Mexilane LS. O psixofarmakoterapii bol’ny’x nevrozami. Vsesoyuzny’j simpozium «Ximiya, farmakologiya i klinika nejroleptikov». Tartu. 1986;140-143. (In Russ.)
  20. Seredenin SB, Voronina TA, Neznamov GG, Zherdev VP. Fenazepam: 25 let v medicinskoj praktike. M.: Nauka; 2007. (In Russ.)
  21. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55. https://doi.org/10.1111/j.2044-8341.1959.tb00467.x
  22. Aleksandrovskij YuA, Rudenko GM, Neznamov GG. Unificirovannaya sistema ocenki kliniko-farmakologicheskogo dejstviya psixotropny’x preparatov u bol’ny’x s pogranichny’mi nervno-psixicheskimi rasstrojstvami. Metod rekomendacii. M. 1984. (In Russ.)
  23. Xanin YuL. Kratkoe rukovodstvo k primeneniyu shkaly’ reaktivnoj i lichnostnoj trevozhnosti Ch.D. Spilbergera. L.: LNIIFK; 1976. (In Russ.)
  24. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39(3):315-325. https://doi.org/10.1016/0022-3999(94)00125-o
  25. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry. 1960;23:56-62. https://doi.org/10.1136/jnnp.23.1.56
  26. Guy W. Clinical Global Impressions Scale. ECDEU Assessment for psychopharmacology. Rev Ed Rockville Maryland. 1976:218-222. https://doi.org/10.1037/t48216-000
  27. Ouimet AJ, Gawronski B, Dozois DJA. Cognitive vulnerability to anxiety: A review and an integrative model. Clin Psychol Rev. 2009;29(6):459-470. https://doi.org/10.1016/j.cpr.2009.05.004
  28. Khan A, Kolts RL, Rapaport MH, Krishnan KRR, Brodhead AE, Brown WA. Magnitude of placebo response and drug-placebo differences across psychiatric disorders. Psychol Med. 2005;35(5):743-749. https://doi.org/10.1017/s0033291704003873
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.